Related references
Note: Only part of the references are listed.Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
Yuan He et al.
NATURE COMMUNICATIONS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
SHP2 is required for BCR-ABL1-induced hematologic neoplasia
S. Gu et al.
LEUKEMIA (2018)
Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide
Jiro Kikuchi et al.
CANCER RESEARCH (2018)
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab
Ahmed T. Kurdi et al.
MOLECULAR CANCER THERAPEUTICS (2018)
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Sara Mainardi et al.
NATURE MEDICINE (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
Kenshi Suzuki et al.
BLOOD CANCER JOURNAL (2018)
Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
Masafumi Taniwaki et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2018)
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos
Pasquale L. Fedele et al.
BLOOD (2018)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
Shinsuke Iida et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
Jun Chen et al.
NATURE (2017)
Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab
Jennifer Postelnek et al.
AAPS JOURNAL (2016)
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak et al.
BLOOD (2016)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
SLAM family receptors in normal immunity and immune pathologies
Ning Wu et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells
Jong R. Kim et al.
IMMUNOBIOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular pathogenesis of multiple myeloma
Yusuke Furukawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
Jiro Kikuchi et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
C. C. Bjorklund et al.
BLOOD CANCER JOURNAL (2015)
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
S. Ozaki et al.
BLOOD CANCER JOURNAL (2015)
Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
Huaijian Guo et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
Zhigang Xie et al.
ONCOTARGET (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
Jiro Kikuchi et al.
BLOOD (2010)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Frits van Rhee et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells
Zhongjun Dong et al.
NATURE IMMUNOLOGY (2009)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces aritibody-dependent cellular cytotoxicity in the bone marrow mitieu
Yu-Tzu Tai et al.
BLOOD (2008)
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella et al.
BLOOD (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the Met receptor tyrosine kinase
CR Maroun et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Share Paper
